You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Which of the following is a new drug approved for the treatment of Breast Cancer? and explain in detail?
Palbociclib: MOA: It acts by inhibiting CDK-4, CDK-6. ROUTE: Oral drug USES: It is approved for Advanced or Metastatic Breast Cancer (ER+ve and HER2-ve) S/E: Neutropenia, Leukopenia, infections, stomatitis, fatigue, nausea, anemia, headache, diarrhea and Thrombocytopenia. Palbociclib is a substrate and an inhibitor of CYP3A4 . Patients should avoid concomitant use of strong CYP3A inhibitors (Indinavir, Itraconazole, Ketoconazole, Lopinavir/Ritonavir etc). Patients should avoid breastfeeding while taking palbociclib. Ruxolitinib It is Janus Kinase inhibitor used for Myelofibrosis Trametinib It is MEK inhibitor used for Malignant Melanoma in combination with Dabrafenib (BRAF inhibitor) Cobimetinib It is MEK inhibitor used for Malignant Melanoma in combination with Vemurafenib (BRAF inhibitor)